SWOG clinical trial number
S9719

Clonal Hematopoiesis as a Marker of Genetic Damage Pilot Study Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence, Ancillary to S9623

Closed
Phase
Accrual
13%
Abbreviated Title
ANCILLARY: Incidence of clonal hematopoiesis in marrow (when available), PBPC products and PB.
Activated
10/15/1997
Closed
02/01/2001
Participants
NCORP, Members, Medical Oncologists, Pathologists

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

Patients on 9623

CANCER CONTROL CREDIT: 0.0
TREATMENT CREDIT: 0.1

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase